Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)
19.2.2025 07:00:00 CET | Business Wire | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications.
Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications.
In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution.
"As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Perkins. “We anticipated this gap and purpose-built SyncMetra to simplify the deployment, configuration, management, and expansion of private 5G networks to open new revenue streams for network owners and their system integrators, VARs and mobile network specialists.”
According to the company, with SyncMetra, IT teams can deploy private 5G networks as easily as Wi-Fi without over-reliance on telco expertise or cost-prohibitive infrastructure unlocking some of the market’s most powerful and promising emerging technologies including AI/ML, IoT, robotics, cloud computing, and edge data inference.
Key Features
The SyncMetrasuite of products introduces new capabilities enabling a programmable, expandable and more affordable alternative to current wireless technologies:
- Deterministic networking supporting real-time communication guaranteed Quality of Service (QoS)
- Ultra-reliable low-latency communications (URLLC), and precise packet delivery
- Software-defined and cloud-managed with centralized orchestration via SyncMetra ManagerTM (SMM)
- Seamless integration with existing IT infrastructure, reducing deployment complexity
- Mission-critical security with complete visibility and programmability
- Expandable architecture that allows businesses to scale as needed
Inquiries related to demonstrations and evaluation units are to be directed to www.canogaperkins.net/contact-2.
About Canoga Perkins
Founded in 1963, privately held Canoga Perkins has a long history of providing mission-critical, secure communications to service providers, the military, government agencies, and utilities. With more than 150,000 active network elements operating in Tier 1 service provider networks, Canoga Perkins is differentiated by the telco reliability of its products and its ability to anticipate and nimbly act on emerging IT trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218480924/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom